At Series D the underwriting shifts from growth potential to durability and exit path. Grow Therapy's record — $150M of $225M lifetime capital in one round — shows the concentration typical of late-stage raises. Prepare for exit-scenario questions, not product questions.
Key takeaways
- Late-stage investors underwrite durability and exit paths, not product potential.
- A round that is two-thirds of lifetime capital concentrates governance influence — read the terms, not just the headline.
- Regulated and reimbursement-driven categories face policy-risk diligence that founders rarely rehearse.
Late rounds are often described as more of the same, only bigger. They are not. The questions change entirely.
The record here belongs to Jake Cooper, founder of Grow Therapy (New York, United States).
| | | |---|---| | Founder | Jake Cooper | | Company | Grow Therapy (New York, United States) | | Total raised | $225M | | Latest round | Series D — $150M | | Round date | June 2026 | | Named participants on record | TCV, Growth Equity at Goldman Sachs Alternatives, BCI, Menlo Ventures |
Two-thirds of lifetime capital arrived in one round, from a mix of growth funds, an institutional asset manager and an existing early backer.
Durability. Not growth rate, but whether revenue persists without proportional spend.
Structural economics. Contribution margin at current scale, and what breaks if volume doubles.
Policy and reimbursement exposure, in any category where a third party determines whether your customer gets paid.
Exit paths. Who buys this, at what multiple, in which market conditions.
If you have not written the exit-scenario memo yourself, someone in the room has, and their version will be less flattering.
When one round is most of your lifetime capital, the investors in it hold disproportionate influence over the next decision — a sale, a down round, a CEO change. That influence sits in the terms, not in the announcement.
Read the protective provisions, the liquidation preference stack and the board composition as one document. Those three together describe who actually decides.
An early-stage fund still writing cheques at Series D has been watching the business for years. Their participation is the most credible signal available to a new lead, and it costs nothing to secure if you have kept them informed.
1. Write the exit-scenario memo before the round opens. 2. Model contribution margin at 2x current volume. 3. Document regulatory and reimbursement dependencies explicitly. 4. Read preferences, protective provisions and board composition together. 5. Secure existing-investor participation before approaching new leads.
Amounts, stages, dates and named participants are documented. Valuation, terms and board composition are not.
Frequently asked questions
- What do Series D investors actually diligence?
- Retention durability, unit economics at scale, competitive moat, regulatory exposure and credible exit routes. Product questions largely disappear.
- Is a very large late round risky for founders?
- It concentrates influence and sets a valuation you must grow into. The risk is not the money; it is the expectation attached to it.
- Where do these figures come from?
- Structured founder funding records: total raised, round stage, round amount, round date and named participants.
